| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011667042 |
| P356 | DOI | 10.1023/A:1005300621350 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1023%2FA%3A1005300621350 |
| https://onlinelibrary.wiley.com/doi/pdf/10.1023/A%3A1005300621350 | ||
| P698 | PubMed publication ID | 9211190 |
| P2093 | author name string | M. S. Hershfield | |
| I. Santisteban | |||
| F. X. Arredondo-Vega | |||
| P2860 | cites work | Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c | Q24309066 |
| Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man | Q24317015 | ||
| Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations | Q27653992 | ||
| Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency | Q71041318 | ||
| Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency | Q71167703 | ||
| Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency | Q72108825 | ||
| Adult presentation of adenosine deaminase deficiency | Q72220530 | ||
| Immunosuppression mediated by an inhibitor of S-adenosyl-L-homocysteine hydrolase. Prevention and treatment of collagen-induced arthritis | Q72817299 | ||
| Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity | Q93729850 | ||
| The recognition of Lesch‐Nyhan syndrome as an inborn error of purine metabolism | Q28242858 | ||
| Adenosine–deaminase–deficient mice die perinatally and exhibit liver–cell degeneration, atelectasis and small intestinal cell death | Q28506780 | ||
| Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice | Q28587434 | ||
| Deduced amino acid sequence of Escherichia coli adenosine deaminase reveals evolutionarily conserved amino acid residues: implications for catalytic function | Q30965351 | ||
| Hot spot mutations in adenosine deaminase deficiency | Q33740382 | ||
| Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype | Q33907756 | ||
| Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency | Q33957895 | ||
| p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. | Q33973822 | ||
| Complete sequence and structure of the gene for human adenosine deaminase | Q34162954 | ||
| T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase | Q34169950 | ||
| Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency | Q34454454 | ||
| Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes | Q34529077 | ||
| IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency | Q35602714 | ||
| Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery | Q35889300 | ||
| Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency. | Q35889409 | ||
| Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin | Q36246013 | ||
| Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation | Q36399151 | ||
| In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients | Q37037882 | ||
| Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines | Q37331315 | ||
| S -Adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin | Q37331491 | ||
| Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity | Q39327898 | ||
| Bcl-2 relieves deoxyadenylate stress and suppresses apoptosis in pre-B leukemia cells. | Q39477925 | ||
| Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease | Q40158483 | ||
| Adenosine deaminase deficiency: molecular basis and recent developments | Q40411058 | ||
| PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency | Q40525169 | ||
| Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine and adenine arabinoside. A basis for direct toxic effects of analogs of adenosine | Q40695710 | ||
| Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy | Q40876241 | ||
| S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine | Q42252652 | ||
| Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase | Q43638744 | ||
| Basis for resistance to 3-deazaaristeromycin, an inhibitor of S-adenosylhomocysteine hydrolase, in human B-lymphoblasts | Q44040642 | ||
| Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency | Q44190198 | ||
| PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years | Q45866741 | ||
| Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients | Q45866834 | ||
| T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. | Q45866838 | ||
| Bone marrow gene transfer in three patients with adenosine deaminase deficiency. | Q45879021 | ||
| Alterations in deoxyribonucleotide metabolism in cultured cells with ribonucleotide reductase activities refractory to feedback inhibition by 2'-deoxyadenosine triphosphate. | Q54547964 | ||
| Role of S-adenosylhomocysteine in adenosine-mediated toxicity in cultured mouse T lymphoma cells | Q67051811 | ||
| Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency | Q67276550 | ||
| Adenosine, deoxyadenosine, and deoxyguanosine induce DNA cleavage in mouse thymocytes | Q68097030 | ||
| In vivo inhibition of mouse liver methyltransferase enzymes following treatment with 2'-deoxycoformycin and 2'-deoxyadenosine | Q68806847 | ||
| Selective inhibition of T cell activation by an inhibitor of S-adenosyl-L-homocysteine hydrolase | Q70649010 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 179-185 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | Journal of Inherited Metabolic Disease | Q6295359 |
| P1476 | title | Clinical expression, genetics and therapy of adenosine deaminase (ADA) deficiency | |
| P478 | volume | 20 |
| Q45871226 | Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations |
| Q34048275 | Adenosine deaminase-related growth factors stimulate cell proliferation in Drosophila by depleting extracellular adenosine |
| Q32063453 | Adenosine deaminase: functional implications and different classes of inhibitors |
| Q37950942 | Primary immunodeficiency diseases associated with neurologic manifestations |
| Q37963491 | The PRPP synthetase spectrum: what does it demonstrate about nucleotide syndromes? |
| Q41521428 | When to investigate for purine and pyrimidine disorders. Introduction and review of clinical and laboratory indications |
Search more.